R1 patients non re–excised (noRE), n =331 | R1 patients re–excised (RE), n =698 | R1 patients re–excised (RE) or not (NoRE) n= 1,029 | p value for R1 patients noRE versus RE | |
---|---|---|---|---|
Gender | ||||
Female | 147 (44%) | 313 (45%) | 460 (44.7%) | Chi-2 p =0.897 |
Male | 184 (56%) | 385 (55%) | 569 (55.3%) | |
Age at diagnostic | 59.5 (21.2) | 57.1 (18.3) | 57.88 (19.31) | Chi 2 p =0.011 |
Site of the tumor | KW p =0.020 | |||
Trunk wall | 134 (41%) | 206 (30%) | 445 (43.2%) | |
Upper limb | 62 (19%) | 182 (26%) | 340 (33.0%) | |
Lower limb | 135 (41%) | 310 (44%) | 244 (23.7%) | |
Size of the tumor (mm) | 72.8 (58.5) | 47.9 (40.5) | 55.75 (48.3) | KW p <0.001 |
Depth of the tumor | 45 (5-500) | Chi-2 p <0.001 | ||
Superficial (Sus–facia) | 89 (29%) | 303 (46%) | 392 (40.9%) | |
Deep (Sub-facia) | 214 (71%) | 352 (54%) | 566 (59.1%) | |
Histology | ||||
Liposarcoma | 62 (19%) | 85 (12%) | 147 (14.3%) | Chi-2 p =0.001 |
Synovial sarcoma | 21 (6%) | 32 (5%) | 53 (5.2%) | |
Leiomyosarcoma | 48 (14%) | 160 (23%) | 208 (20.2%) | |
Miscellaneous sarcomas | 46 (14%) | 76 (11%) | 122 (11.9%) | |
Myxofibrosarcoma | 38 (11%) | 115 (16%) | 153 (14.9%) | |
Undifferentiated pleomorphic sarcoma | 78 (24%) | 153 (22%) | 231 (22.4%) | |
Other | 38 (11%) | 77 (11%) | 115 (11.2%) | |
Grade of the tumor | ||||
Grade 1 | 43 (14%) | 101 (15%) | 144 (15.1%) | Chi-2 p =0.106 |
Grade 2 | 81 (27%) | 227 (35%) | 308 (32.4%) | |
Grade 3 | 98 (33%) | 193 (29%) | 291 (30.6%) | |
Non dimmable | 74 (25%) | 135 (21%) | 209 (22.0%) | |
MDTB before treatment | ||||
No | 286 (86%) | 642 (92%) | 928 (90.2%) | Chi-2 p =0.005 |
Yes | 45 (14%) | 56 (8%) | 101 (9.8%) | |
2d surgery performed | ||||
Inside NETSARC | – | 490 (70%) | 490 (47.6%) | |
Outside NETSARC | – | 175 (25%) | 175 (17.0%) | |
Unkwown | – | 33 (5%) | 33 (3.2%) | |
Quality of resection | ||||
R0 | 0 (0%) | 599 (86%) | 599 (60.4%) | Chi-2 p <0.001 |
R1 | 331(100%) | 42 (6%) | 373 (37.6%) | |
Margins not evaluable | 0 (0%) | 2 (0%) | 2 (0%) | |
Not specified | 0 (0%) | 55 (8%) | 55 (5.3%) |